DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nucynta (Tapentadol Hydrochloride) - Summary

 
 



NUCYNTA SUMMARY

NUCYNTA® (tapentadol) is a mu-opioid receptor agonist, supplied in immediate-release film-coated tablets for oral administration, containing 58.24, 87.36 and 116.48 mg of tapentadol hydrochloride in each tablet strength, corresponding to 50, 75, and 100 mg of tapentadol free-base, respectively.

NUCYNTA® (tapentadol) is indicated for the management of moderate to severe acute pain in adults.


See all Nucynta indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Nucynta (Tapentadol)

Pain, Papular Lesions, a Trip to Pakistan: Crack the Case
Source: Medscape Infectious Diseases Headlines [2015.08.19]
Dr Paget discusses one of his recent patients who returned from a trip to Pakistan 5 years ago and since then has never been the same.
Medscape Rheumatology

NeuroBreak: OxyContin for Kids, Singing Away the Pain
Source: MedPage Today Neurology [2015.08.18]
(MedPage Today) -- News and commentary from the world of neurology and neuroscience

Florida Laws May Help Lower Abuse of Prescription Painkillers
Source: MedicineNet Chronic Pain Specialty [2015.08.18]
Title: Florida Laws May Help Lower Abuse of Prescription Painkillers
Category: Health News
Created: 8/17/2015 12:00:00 AM
Last Editorial Review: 8/18/2015 12:00:00 AM

25 Million U.S. Adults Struggle With Daily Pain
Source: MedicineNet Chronic Pain Specialty [2015.08.18]
Title: 25 Million U.S. Adults Struggle With Daily Pain
Category: Health News
Created: 8/18/2015 12:00:00 AM
Last Editorial Review: 8/18/2015 12:00:00 AM

Yeast's New Use: Making Narcotic Painkillers
Source: MedicineNet Chronic Pain Specialty [2015.08.14]
Title: Yeast's New Use: Making Narcotic Painkillers
Category: Health News
Created: 8/13/2015 12:00:00 AM
Last Editorial Review: 8/14/2015 12:00:00 AM

more news >>

Published Studies Related to Nucynta (Tapentadol)

Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. [2014]
decrease in noxious heat stimulation)... CONCLUSIONS: Tapentadol's analgesic effect in chronic pain patients with DPN is

Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. [2014]
patients with hypertension... CONCLUSION: No clinically meaningful mean changes in heart rate or blood pressure

Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain. [2013]
OBJECTIVES: Constipation is a common side effect of opioid therapy. Tapentadol immediate release (IR) was better tolerated than oxycodone IR in 2 clinical trials involving patients with low back or osteoarthritis pain... DISCUSSION: Patient-reported bowel function associated with tapentadol IR treatment was similar to that associated with placebo (10-d trial) and significantly better than that associated with oxycodone IR treatment (10- and 90-d trials).

Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. [2012]
OBJECTIVE: To compare the effects of tapentadol-extended release versus oxycodone-controlled release for pain relief on productivity by combining evidence from different sources.

Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.

more studies >>

Clinical Trials Related to Nucynta (Tapentadol)

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin [Recruiting]
The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects requiring additional analgesia after titration to tapentadol PR 300 mg per day.

This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject reported outcomes. Since, severe low back pain with a neuropathic component, the targeted study population, is frequently treated with a combination therapy (monotherapy is often not effective enough) it is of interest to determine if tapentadol alone (combining 2 mechanisms of action in a single molecule) could be as effective as a combination of tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus combination are of interest.

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Recruiting]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy [Recruiting]
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR 50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours (SPID48) to measure analgesic effect in Korean patients with acute pain following bunionectomy.

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain [Not yet recruiting]

A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain [Not yet recruiting]

more trials >>

Reports of Suspected Nucynta (Tapentadol) Side Effects

Hallucination (21)Drug Ineffective (20)Dizziness (20)Dyspnoea (20)Nausea (19)Confusional State (17)Feeling Abnormal (17)Depression (16)Withdrawal Syndrome (16)Anxiety (14)more >>


Page last updated: 2015-08-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015